Yun Yen - Jan 20, 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Yun Yen
Stock symbol
LIXT
Transactions as of
Jan 20, 2025
Transactions value $
$0
Form type
4
Date filed
1/22/2025, 01:20 PM
Previous filing
Oct 29, 2024
Next filing
Apr 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +4.55K $0.00 4.55K Jan 20, 2025 Common 4.55K $2.33 Direct F1
holding LIXT Options to Purchase Common Stock 5.79K Jan 20, 2025 Common 5.79K $1.30 Direct
holding LIXT Options to Purchase Common Stock 10K Jan 20, 2025 Common 10K $2.37 Direct
holding LIXT Options to Purchase Common Stock 4.53K Jan 20, 2025 Common 4.53K $2.37 Direct
holding LIXT Options to Purchase Common Stock 10K Jan 20, 2025 Common 10K $7.45 Direct
holding LIXT Options to Purchase Common Stock 10K Jan 20, 2025 Common 10K $30.30 Direct
holding LIXT Options to Purchase Common Stock 5K Jan 20, 2025 Common 5K $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 5.26K Jan 20, 2025 Common 5.26K $57.00 By Sino-American Cancer FDD
holding LIXT Options to Purchase Common Stock 3.33K Jan 20, 2025 Common 3.33K $16.80 Direct
holding LIXT Options to Purchase Common Stock 833 Jan 20, 2025 Common 833 $66.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,545 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.